Evidence map›Paper›PMID 38072941›Full record

ArticleBlood cancer journal2023

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.

Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz and 12 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Charalampos CharalampousDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Utkarsh GoelDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Prashant KapoorDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-4342-364X
Moritz BinderDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9014-9658
Francis K BuadiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-3214-0203
Joselle CookDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5335-9533
David DingliDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Angela DispenzieriDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8780-9512
Amie L FonderDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Morie A GertzDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3853-5196
Wilson GonsalvesDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Suzanne R HaymanDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Miriam A HobbsDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Yi L HwaDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Taxiarchis KourelisDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8573-9434
Martha Q LacyDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Nelson LeungDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Yi LinDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1556-6416
Rahma WarsameDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Robert A KyleDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
S Vincent RajkumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5862-1833
Shaji K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.ORCID 0000-0001-5392-9284
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaNeoplasms, Plasma CellAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansAntibodies, MonoclonaldaratumumabDexamethasone

Identifiers

PMID38072941
PMCPMC10711005
OpenAlexW4389556067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.